Ritter Pharmaceuticals, Inc. (RTTR) EPS Estimated At $-0.05

February 14, 2018 - By Stephen Andrade

 Ritter Pharmaceuticals, Inc. (RTTR) EPS Estimated At $ 0.05

Analysts expect Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) to report $-0.05 EPS on February, 26.They anticipate $0.69 EPS change or 93.24 % from last quarter’s $-0.74 EPS. After having $-0.14 EPS previously, Ritter Pharmaceuticals, Inc.’s analysts see -64.29 % EPS growth. The stock increased 1.28% or $0.0038 during the last trading session, reaching $0.3018. About 199,997 shares traded. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has declined 56.21% since February 14, 2017 and is downtrending. It has underperformed by 72.91% the S&P500.

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Ratings Coverage

Among 5 analysts covering Ritter Pharmaceuticals (NASDAQ:RTTR), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ritter Pharmaceuticals had 9 analyst reports since December 2, 2015 according to SRatingsIntel. Chardan Capital Markets maintained the shares of RTTR in report on Tuesday, October 25 with “Buy” rating. Roth Capital maintained the stock with “Buy” rating in Monday, June 5 report. The rating was maintained by Maxim Group on Wednesday, July 5 with “Hold”. The firm has “Hold” rating by Maxim Group given on Friday, August 4. The company was initiated on Thursday, April 14 by Maxim Group. As per Monday, October 23, the company rating was maintained by H.C. Wainwright. Chardan Capital Markets initiated Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) rating on Wednesday, December 2. Chardan Capital Markets has “Buy” rating and $3 target. Rodman & Renshaw initiated the stock with “Buy” rating in Wednesday, January 4 report.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company has market cap of $14.94 million. The Company’s lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. It currently has negative earnings. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine.

More notable recent Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) news were published by: Globenewswire.com which released: “Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on …” on November 29, 2017, also Labusinessjournal.com with their article: “Ritter Pharma Raises $23 million to Test Lactose Intolerance Treatment” published on October 04, 2017, Globenewswire.com published: “Ritter Pharmaceuticals, Inc. Prices $23000000 Public Offering” on September 29, 2017. More interesting news about Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) were released by: Globenewswire.com and their article: “Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business …” published on November 02, 2017 as well as Globenewswire.com‘s news article titled: “Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical …” with publication date: January 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.